Aurinia Pharmaceuticals Inc. (AUPH)
$9.29
+0.55 (+6.29%)
Rating:
Recommendation:
Neutral
Symbol | AUPH |
---|---|
Price | $9.29 |
Beta | 1.160 |
Volume Avg. | 3.26M |
Market Cap | 1.325B |
Shares () | - |
52 Week Range | 4.07-13.415 |
1y Target Est | - |
DCF Unlevered | AUPH DCF -> | |
---|---|---|
DCF Levered | AUPH LDCF -> | |
ROE | -25.44% | Sell |
ROA | -22.97% | Sell |
Operating Margin | - | |
Debt / Equity | 16.14% | Neutral |
P/E | -12.73 | Strong Sell |
P/B | 3.25 | Strong Buy |
Latest AUPH news
About
Download (Excel)Mr. Peter S. Greenleaf M.B.A.
Healthcare
Biotechnology
NASDAQ Global Market
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.